NO331971B1 - Anvendelse av en IL-18-inhibitor, en ekspresjonsvektor som omfatter den kodende sekvensen til IL-18 bindende protein og en celle som har blitt genetisk modifisert for a produsere en inhibitor av IL-18-bindende protein, i fremstillingen av et medikament for behandling og/eller forebygging av alkoholisk hepatitt. - Google Patents

Anvendelse av en IL-18-inhibitor, en ekspresjonsvektor som omfatter den kodende sekvensen til IL-18 bindende protein og en celle som har blitt genetisk modifisert for a produsere en inhibitor av IL-18-bindende protein, i fremstillingen av et medikament for behandling og/eller forebygging av alkoholisk hepatitt. Download PDF

Info

Publication number: NO331971B1
Authority: NO; Norway
Prior art keywords: inhibitor; use according; tnf; liver; binding protein
Prior art date: 2000-02-21

Application number

NO20023962A

Other languages

English (en)

Norwegian (no)

Other versions

NO20023962D0 (no

NO20023962L (no

Inventor

Daniela Novick

Menachem Rubinstein

Charles Dinarello

Yolande Chvatchko

Christine Plater-Zyberk

Santer Van Deventer

Soo-Hyun Kim

Original Assignee

Yeda Res & Dev

Merck Serono Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-02-21

Filing date

2002-08-20

Publication date

2012-05-14

2002-08-20 Application filed by Yeda Res & Dev, Merck Serono Sa filed Critical Yeda Res & Dev

2002-08-20 Publication of NO20023962D0 publication Critical patent/NO20023962D0/no

2002-08-20 Publication of NO20023962L publication Critical patent/NO20023962L/no

2012-05-14 Publication of NO331971B1 publication Critical patent/NO331971B1/no

Links

108090000171 Interleukin-18 Proteins 0.000 title claims abstract description 203
102000003810 Interleukin-18 Human genes 0.000 title claims abstract description 202
239000003112 inhibitor Substances 0.000 title claims abstract description 77
239000003814 drug Substances 0.000 title claims abstract description 41
238000011282 treatment Methods 0.000 title claims abstract description 41
238000004519 manufacturing process Methods 0.000 title claims abstract description 36
102000044166 interleukin-18 binding protein Human genes 0.000 title claims description 123
108010070145 interleukin-18 binding protein Proteins 0.000 title claims description 123
206010019728 Hepatitis alcoholic Diseases 0.000 title claims description 29
208000002353 alcoholic hepatitis Diseases 0.000 title claims description 29
230000002265 prevention Effects 0.000 title claims description 9
239000013604 expression vector Substances 0.000 title claims description 8
108091026890 Coding region Proteins 0.000 title claims description 6
206010067125 Liver injury Diseases 0.000 claims abstract description 49
231100000234 hepatic damage Toxicity 0.000 claims abstract description 40
230000008818 liver damage Effects 0.000 claims abstract description 40
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 77
108090000623 proteins and genes Proteins 0.000 claims description 66
102000004169 proteins and genes Human genes 0.000 claims description 56
230000000694 effects Effects 0.000 claims description 40
239000005557 antagonist Substances 0.000 claims description 34
229940079593 drug Drugs 0.000 claims description 32
230000037396 body weight Effects 0.000 claims description 24
102000014150 Interferons Human genes 0.000 claims description 15
108010050904 Interferons Proteins 0.000 claims description 15
238000002360 preparation method Methods 0.000 claims description 14
108060003951 Immunoglobulin Proteins 0.000 claims description 13
102000001708 Protein Isoforms Human genes 0.000 claims description 13
108010029485 Protein Isoforms Proteins 0.000 claims description 13
102000018358 immunoglobulin Human genes 0.000 claims description 13
229940079322 interferon Drugs 0.000 claims description 12
230000001684 chronic effect Effects 0.000 claims description 8
229940111134 coxibs Drugs 0.000 claims description 6
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 6
229940124638 COX inhibitor Drugs 0.000 claims description 5
108020001507 fusion proteins Proteins 0.000 claims description 2
102000037865 fusion proteins Human genes 0.000 claims description 2
238000001415 gene therapy Methods 0.000 claims description 2
102000003390 tumor necrosis factor Human genes 0.000 claims 3
101710097638 Soluble TNF receptor II Proteins 0.000 claims 1
208000011231 Crohn disease Diseases 0.000 abstract description 23
206010003246 arthritis Diseases 0.000 abstract description 23
206010009900 Colitis ulcerative Diseases 0.000 abstract description 14
201000006704 Ulcerative Colitis Diseases 0.000 abstract description 14
208000022559 Inflammatory bowel disease Diseases 0.000 abstract description 12
201000003068 rheumatic fever Diseases 0.000 abstract description 4
102100040247 Tumor necrosis factor Human genes 0.000 description 69
241000699670 Mus sp. Species 0.000 description 60
235000018102 proteins Nutrition 0.000 description 52
239000002158 endotoxin Substances 0.000 description 51
108010074328 Interferon-gamma Proteins 0.000 description 48
102100037850 Interferon gamma Human genes 0.000 description 46
229920006008 lipopolysaccharide Polymers 0.000 description 42
210000004185 liver Anatomy 0.000 description 42
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 41
201000010099 disease Diseases 0.000 description 37
210000004027 cell Anatomy 0.000 description 33
230000014509 gene expression Effects 0.000 description 32
230000001965 increasing effect Effects 0.000 description 32
210000002966 serum Anatomy 0.000 description 29
108020004999 messenger RNA Proteins 0.000 description 27
102000004127 Cytokines Human genes 0.000 description 26
108090000695 Cytokines Proteins 0.000 description 26
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
102000005962 receptors Human genes 0.000 description 25
108020003175 receptors Proteins 0.000 description 24
206010061218 Inflammation Diseases 0.000 description 22
230000006378 damage Effects 0.000 description 22
230000004054 inflammatory process Effects 0.000 description 22
102100035904 Caspase-1 Human genes 0.000 description 21
108090000426 Caspase-1 Proteins 0.000 description 21
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 21
230000027455 binding Effects 0.000 description 18
238000002347 injection Methods 0.000 description 18
239000007924 injection Substances 0.000 description 18
238000000034 method Methods 0.000 description 17
230000003612 virological effect Effects 0.000 description 17
235000001014 amino acid Nutrition 0.000 description 16
230000000770 proinflammatory effect Effects 0.000 description 16
241001529936 Murinae Species 0.000 description 14
241000699666 Mus <mouse, genus> Species 0.000 description 14
208000019425 cirrhosis of liver Diseases 0.000 description 14
208000019423 liver disease Diseases 0.000 description 14
102100036475 Alanine aminotransferase 1 Human genes 0.000 description 13
108010082126 Alanine transaminase Proteins 0.000 description 13
206010016654 Fibrosis Diseases 0.000 description 13
229940024606 amino acid Drugs 0.000 description 13
150000001413 amino acids Chemical class 0.000 description 13
210000001072 colon Anatomy 0.000 description 13
238000011161 development Methods 0.000 description 13
230000018109 developmental process Effects 0.000 description 13
239000011780 sodium chloride Substances 0.000 description 13
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 12
208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 12
208000033222 Biliary cirrhosis primary Diseases 0.000 description 12
208000012654 Primary biliary cholangitis Diseases 0.000 description 12
125000000539 amino acid group Chemical group 0.000 description 12
208000006454 hepatitis Diseases 0.000 description 12
206010008909 Chronic Hepatitis Diseases 0.000 description 11
108010062580 Concanavalin A Proteins 0.000 description 11
102000004388 Interleukin-4 Human genes 0.000 description 11
108090000978 Interleukin-4 Proteins 0.000 description 11
230000004913 activation Effects 0.000 description 11
210000000013 bile duct Anatomy 0.000 description 11
230000007882 cirrhosis Effects 0.000 description 11
108090000765 processed proteins & peptides Proteins 0.000 description 11
208000022309 Alcoholic Liver disease Diseases 0.000 description 10
102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 10
108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 10
238000006243 chemical reaction Methods 0.000 description 10
210000001503 joint Anatomy 0.000 description 10
241000186427 Cutibacterium acnes Species 0.000 description 9
206010019755 Hepatitis chronic active Diseases 0.000 description 9
108010065805 Interleukin-12 Proteins 0.000 description 9
102000013462 Interleukin-12 Human genes 0.000 description 9
241001465754 Metazoa Species 0.000 description 9
241000700159 Rattus Species 0.000 description 9
210000001744 T-lymphocyte Anatomy 0.000 description 9
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 9
210000000845 cartilage Anatomy 0.000 description 9
210000001612 chondrocyte Anatomy 0.000 description 9
231100000283 hepatitis Toxicity 0.000 description 9
238000010172 mouse model Methods 0.000 description 9
102000004196 processed proteins & peptides Human genes 0.000 description 9
230000002829 reductive effect Effects 0.000 description 9
238000006467 substitution reaction Methods 0.000 description 9
210000001519 tissue Anatomy 0.000 description 9
102000003298 tumor necrosis factor receptor Human genes 0.000 description 9
208000023275 Autoimmune disease Diseases 0.000 description 8
108090000467 Interferon-beta Proteins 0.000 description 8
230000004071 biological effect Effects 0.000 description 8
230000006870 function Effects 0.000 description 8
208000002672 hepatitis B Diseases 0.000 description 8
208000015181 infectious disease Diseases 0.000 description 8
230000005764 inhibitory process Effects 0.000 description 8
229940117681 interleukin-12 Drugs 0.000 description 8
206010039073 rheumatoid arthritis Diseases 0.000 description 8
208000024891 symptom Diseases 0.000 description 8
102000004190 Enzymes Human genes 0.000 description 7
108090000790 Enzymes Proteins 0.000 description 7
108010002350 Interleukin-2 Proteins 0.000 description 7
102000000588 Interleukin-2 Human genes 0.000 description 7
102000015696 Interleukins Human genes 0.000 description 7
108010063738 Interleukins Proteins 0.000 description 7
241000589517 Pseudomonas aeruginosa Species 0.000 description 7
239000002299 complementary DNA Substances 0.000 description 7
230000002596 correlated effect Effects 0.000 description 7
230000034994 death Effects 0.000 description 7
230000008105 immune reaction Effects 0.000 description 7
230000001976 improved effect Effects 0.000 description 7
238000001727 in vivo Methods 0.000 description 7
230000002757 inflammatory effect Effects 0.000 description 7
238000007912 intraperitoneal administration Methods 0.000 description 7
210000002540 macrophage Anatomy 0.000 description 7
210000004400 mucous membrane Anatomy 0.000 description 7
230000003472 neutralizing effect Effects 0.000 description 7
230000003349 osteoarthritic effect Effects 0.000 description 7
201000008482 osteoarthritis Diseases 0.000 description 7
230000001575 pathological effect Effects 0.000 description 7
229920001184 polypeptide Polymers 0.000 description 7
230000001105 regulatory effect Effects 0.000 description 7
230000004083 survival effect Effects 0.000 description 7
102000004557 Interleukin-18 Receptors Human genes 0.000 description 6
108010017537 Interleukin-18 Receptors Proteins 0.000 description 6
239000002202 Polyethylene glycol Substances 0.000 description 6
241000700605 Viruses Species 0.000 description 6
230000009471 action Effects 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
239000012530 fluid Substances 0.000 description 6
238000003780 insertion Methods 0.000 description 6
230000037431 insertion Effects 0.000 description 6
229940047122 interleukins Drugs 0.000 description 6
239000003446 ligand Substances 0.000 description 6
230000001404 mediated effect Effects 0.000 description 6
210000005087 mononuclear cell Anatomy 0.000 description 6
230000003041 necroinflammatory effect Effects 0.000 description 6
229920001223 polyethylene glycol Polymers 0.000 description 6
239000002243 precursor Substances 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
241000588724 Escherichia coli Species 0.000 description 5
101001019591 Homo sapiens Interleukin-18-binding protein Proteins 0.000 description 5
102100026720 Interferon beta Human genes 0.000 description 5
102100035017 Interleukin-18-binding protein Human genes 0.000 description 5
102000004889 Interleukin-6 Human genes 0.000 description 5
108090001005 Interleukin-6 Proteins 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
210000000447 Th1 cell Anatomy 0.000 description 5
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
239000000427 antigen Substances 0.000 description 5
230000001363 autoimmune Effects 0.000 description 5
230000009286 beneficial effect Effects 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
206010012601 diabetes mellitus Diseases 0.000 description 5
210000002683 foot Anatomy 0.000 description 5
239000012634 fragment Substances 0.000 description 5
231100000753 hepatic injury Toxicity 0.000 description 5
230000005847 immunogenicity Effects 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
208000002551 irritable bowel syndrome Diseases 0.000 description 5
KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 5
229960004963 mesalazine Drugs 0.000 description 5
230000036470 plasma concentration Effects 0.000 description 5
238000003757 reverse transcription PCR Methods 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
102000019034 Chemokines Human genes 0.000 description 4
108010012236 Chemokines Proteins 0.000 description 4
108020004414 DNA Proteins 0.000 description 4
206010012735 Diarrhoea Diseases 0.000 description 4
238000002965 ELISA Methods 0.000 description 4
208000009386 Experimental Arthritis Diseases 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
208000005176 Hepatitis C Diseases 0.000 description 4
102000000589 Interleukin-1 Human genes 0.000 description 4
108010002352 Interleukin-1 Proteins 0.000 description 4
108010058846 Ovalbumin Proteins 0.000 description 4
125000003275 alpha amino acid group Chemical group 0.000 description 4
230000003110 anti-inflammatory effect Effects 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
210000001188 articular cartilage Anatomy 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
210000004204 blood vessel Anatomy 0.000 description 4
230000015556 catabolic process Effects 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
239000003246 corticosteroid Substances 0.000 description 4
238000012217 deletion Methods 0.000 description 4
230000037430 deletion Effects 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
210000002889 endothelial cell Anatomy 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
230000004761 fibrosis Effects 0.000 description 4
210000001035 gastrointestinal tract Anatomy 0.000 description 4
230000002440 hepatic effect Effects 0.000 description 4
210000004024 hepatic stellate cell Anatomy 0.000 description 4
239000003018 immunosuppressive agent Substances 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
230000031037 interleukin-18 production Effects 0.000 description 4
238000011835 investigation Methods 0.000 description 4
210000001865 kupffer cell Anatomy 0.000 description 4
239000010410 layer Substances 0.000 description 4
231100000636 lethal dose Toxicity 0.000 description 4
230000001665 lethal effect Effects 0.000 description 4
231100000225 lethality Toxicity 0.000 description 4
230000003859 lipid peroxidation Effects 0.000 description 4
210000005228 liver tissue Anatomy 0.000 description 4
238000005259 measurement Methods 0.000 description 4
210000001616 monocyte Anatomy 0.000 description 4
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
229940092253 ovalbumin Drugs 0.000 description 4
208000007232 portal hypertension Diseases 0.000 description 4
239000000047 product Substances 0.000 description 4
230000004044 response Effects 0.000 description 4
230000019491 signal transduction Effects 0.000 description 4
210000000813 small intestine Anatomy 0.000 description 4
210000000952 spleen Anatomy 0.000 description 4
230000000638 stimulation Effects 0.000 description 4
230000008961 swelling Effects 0.000 description 4
208000011580 syndromic disease Diseases 0.000 description 4
238000012546 transfer Methods 0.000 description 4
239000013598 vector Substances 0.000 description 4
102000000844 Cell Surface Receptors Human genes 0.000 description 3
108010001857 Cell Surface Receptors Proteins 0.000 description 3
208000000419 Chronic Hepatitis B Diseases 0.000 description 3
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
208000032843 Hemorrhage Diseases 0.000 description 3
101000960954 Homo sapiens Interleukin-18 Proteins 0.000 description 3
101500028161 Homo sapiens Tumor necrosis factor-binding protein 1 Proteins 0.000 description 3
102000003996 Interferon-beta Human genes 0.000 description 3
102000003814 Interleukin-10 Human genes 0.000 description 3
108090000174 Interleukin-10 Proteins 0.000 description 3
206010024652 Liver abscess Diseases 0.000 description 3
102000008108 Osteoprotegerin Human genes 0.000 description 3
108010035042 Osteoprotegerin Proteins 0.000 description 3
108091005804 Peptidases Proteins 0.000 description 3
102000035195 Peptidases Human genes 0.000 description 3
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 3
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 3
239000004365 Protease Substances 0.000 description 3
102400000089 Tumor necrosis factor-binding protein 1 Human genes 0.000 description 3
208000036142 Viral infection Diseases 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
231100000439 acute liver injury Toxicity 0.000 description 3
125000002252 acyl group Chemical group 0.000 description 3
208000010002 alcoholic liver cirrhosis Diseases 0.000 description 3
230000002917 arthritic effect Effects 0.000 description 3
238000001574 biopsy Methods 0.000 description 3
230000000740 bleeding effect Effects 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
210000001124 body fluid Anatomy 0.000 description 3
239000010839 body fluid Substances 0.000 description 3
230000008859 change Effects 0.000 description 3
208000037976 chronic inflammation Diseases 0.000 description 3
235000005687 corn oil Nutrition 0.000 description 3
239000002285 corn oil Substances 0.000 description 3
229960004397 cyclophosphamide Drugs 0.000 description 3
230000003013 cytotoxicity Effects 0.000 description 3
231100000135 cytotoxicity Toxicity 0.000 description 3
230000003828 downregulation Effects 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
230000003628 erosive effect Effects 0.000 description 3
210000003494 hepatocyte Anatomy 0.000 description 3
102000043959 human IL18 Human genes 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
238000003364 immunohistochemistry Methods 0.000 description 3
208000027866 inflammatory disease Diseases 0.000 description 3
208000014674 injury Diseases 0.000 description 3
230000003993 interaction Effects 0.000 description 3
229960001388 interferon-beta Drugs 0.000 description 3
229940047124 interferons Drugs 0.000 description 3
230000000968 intestinal effect Effects 0.000 description 3
210000002490 intestinal epithelial cell Anatomy 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
231100000518 lethal Toxicity 0.000 description 3
210000005229 liver cell Anatomy 0.000 description 3
210000001165 lymph node Anatomy 0.000 description 3
230000035800 maturation Effects 0.000 description 3
239000003226 mitogen Substances 0.000 description 3
239000000203 mixture Substances 0.000 description 3
210000000822 natural killer cell Anatomy 0.000 description 3
210000000440 neutrophil Anatomy 0.000 description 3
230000001717 pathogenic effect Effects 0.000 description 3
230000037361 pathway Effects 0.000 description 3
230000008569 process Effects 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
230000028327 secretion Effects 0.000 description 3
230000002269 spontaneous effect Effects 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
210000001258 synovial membrane Anatomy 0.000 description 3
PFBLRDXPNUJYJM-UHFFFAOYSA-N tert-butyl 2-methylpropaneperoxoate Chemical compound CC(C)C(=O)OOC(C)(C)C PFBLRDXPNUJYJM-UHFFFAOYSA-N 0.000 description 3
238000012360 testing method Methods 0.000 description 3
210000002700 urine Anatomy 0.000 description 3
LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 2
MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 2
102000007469 Actins Human genes 0.000 description 2
108010085238 Actins Proteins 0.000 description 2
208000007848 Alcoholism Diseases 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
206010003011 Appendicitis Diseases 0.000 description 2
206010003445 Ascites Diseases 0.000 description 2
206010003827 Autoimmune hepatitis Diseases 0.000 description 2
206010056375 Bile duct obstruction Diseases 0.000 description 2
108010075254 C-Peptide Proteins 0.000 description 2
238000011740 C57BL/6 mouse Methods 0.000 description 2
238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
102000001902 CC Chemokines Human genes 0.000 description 2
108010040471 CC Chemokines Proteins 0.000 description 2
108050006947 CXC Chemokine Proteins 0.000 description 2
102000019388 CXC chemokine Human genes 0.000 description 2
102000014914 Carrier Proteins Human genes 0.000 description 2
206010009208 Cirrhosis alcoholic Diseases 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
208000037487 Endotoxemia Diseases 0.000 description 2
101150064015 FAS gene Proteins 0.000 description 2
201000006107 Familial adenomatous polyposis Diseases 0.000 description 2
206010016717 Fistula Diseases 0.000 description 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
241000711549 Hepacivirus C Species 0.000 description 2
208000027761 Hepatic autoimmune disease Diseases 0.000 description 2
206010019799 Hepatitis viral Diseases 0.000 description 2
206010019851 Hepatotoxicity Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
101500028163 Homo sapiens Tumor necrosis factor-binding protein 2 Proteins 0.000 description 2
101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 2
208000004575 Infectious Arthritis Diseases 0.000 description 2
102000003777 Interleukin-1 beta Human genes 0.000 description 2
108090000193 Interleukin-1 beta Proteins 0.000 description 2
102000019223 Interleukin-1 receptor Human genes 0.000 description 2
108050006617 Interleukin-1 receptor Proteins 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
208000003456 Juvenile Arthritis Diseases 0.000 description 2
206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 2
108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 2
208000002720 Malnutrition Diseases 0.000 description 2
102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 2
108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 2
102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
206010028813 Nausea Diseases 0.000 description 2
206010028851 Necrosis Diseases 0.000 description 2
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
208000031481 Pathologic Constriction Diseases 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
230000006044 T cell activation Effects 0.000 description 2
230000006052 T cell proliferation Effects 0.000 description 2
210000000662 T-lymphocyte subset Anatomy 0.000 description 2
108700012920 TNF Proteins 0.000 description 2
210000004241 Th2 cell Anatomy 0.000 description 2
101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 2
102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 2
102400000091 Tumor necrosis factor-binding protein 2 Human genes 0.000 description 2
206010047700 Vomiting Diseases 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
102100035558 Zinc finger protein GLI2 Human genes 0.000 description 2
210000000683 abdominal cavity Anatomy 0.000 description 2
230000035508 accumulation Effects 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
239000013543 active substance Substances 0.000 description 2
208000026816 acute arthritis Diseases 0.000 description 2
206010001584 alcohol abuse Diseases 0.000 description 2
208000025746 alcohol use disease Diseases 0.000 description 2
230000001476 alcoholic effect Effects 0.000 description 2
210000003423 ankle Anatomy 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
230000008901 benefit Effects 0.000 description 2
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
210000000941 bile Anatomy 0.000 description 2
108091008324 binding proteins Proteins 0.000 description 2
230000008827 biological function Effects 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
230000020411 cell activation Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000006020 chronic inflammation Effects 0.000 description 2
208000029664 classic familial adenomatous polyposis Diseases 0.000 description 2
238000010367 cloning Methods 0.000 description 2
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
230000001276 controlling effect Effects 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
102000026898 cytokine binding proteins Human genes 0.000 description 2
108091008470 cytokine binding proteins Proteins 0.000 description 2
230000016396 cytokine production Effects 0.000 description 2
102000003675 cytokine receptors Human genes 0.000 description 2
108010057085 cytokine receptors Proteins 0.000 description 2
210000004443 dendritic cell Anatomy 0.000 description 2
230000008021 deposition Effects 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
238000010586 diagram Methods 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
210000000981 epithelium Anatomy 0.000 description 2
210000003238 esophagus Anatomy 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
235000021323 fish oil Nutrition 0.000 description 2
230000003890 fistula Effects 0.000 description 2
208000007386 hepatic encephalopathy Diseases 0.000 description 2
208000005252 hepatitis A Diseases 0.000 description 2
231100000304 hepatotoxicity Toxicity 0.000 description 2
230000007686 hepatotoxicity Effects 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
229940125721 immunosuppressive agent Drugs 0.000 description 2
229940124589 immunosuppressive drug Drugs 0.000 description 2
229960000598 infliximab Drugs 0.000 description 2
238000001802 infusion Methods 0.000 description 2
208000018937 joint inflammation Diseases 0.000 description 2
239000002502 liposome Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000004807 localization Effects 0.000 description 2
231100000053 low toxicity Toxicity 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
230000001071 malnutrition Effects 0.000 description 2
235000000824 malnutrition Nutrition 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
238000000386 microscopy Methods 0.000 description 2
238000013425 morphometry Methods 0.000 description 2
230000008693 nausea Effects 0.000 description 2
230000017074 necrotic cell death Effects 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
208000015380 nutritional deficiency disease Diseases 0.000 description 2
XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 2
230000008506 pathogenesis Effects 0.000 description 2
230000007170 pathology Effects 0.000 description 2
230000002085 persistent effect Effects 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
102000040430 polynucleotide Human genes 0.000 description 2
108091033319 polynucleotide Proteins 0.000 description 2
239000002157 polynucleotide Substances 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000007115 recruitment Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
201000001223 septic arthritis Diseases 0.000 description 2
239000000243 solution Substances 0.000 description 2
210000004989 spleen cell Anatomy 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
210000005222 synovial tissue Anatomy 0.000 description 2
230000009897 systematic effect Effects 0.000 description 2
-1 that is Proteins 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
201000001862 viral hepatitis Diseases 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
230000008673 vomiting Effects 0.000 description 2
239000002699 waste material Substances 0.000 description 2
238000001262 western blot Methods 0.000 description 2
208000004998 Abdominal Pain Diseases 0.000 description 1
206010056519 Abdominal infection Diseases 0.000 description 1
206010000087 Abdominal pain upper Diseases 0.000 description 1
208000020154 Acnes Diseases 0.000 description 1
208000030090 Acute Disease Diseases 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
206010053555 Arthritis bacterial Diseases 0.000 description 1
108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
241000283707 Capra Species 0.000 description 1
206010007733 Catabolic state Diseases 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
102000001327 Chemokine CCL5 Human genes 0.000 description 1
108010055166 Chemokine CCL5 Proteins 0.000 description 1
208000006154 Chronic hepatitis C Diseases 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
206010010317 Congenital absence of bile ducts Diseases 0.000 description 1
206010010941 Coombs positive haemolytic anaemia Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
101000828805 Cowpox virus (strain Brighton Red) Serine proteinase inhibitor 2 Proteins 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
102100025137 Early activation antigen CD69 Human genes 0.000 description 1
208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
101710146739 Enterotoxin Proteins 0.000 description 1
108700039887 Essential Genes Proteins 0.000 description 1
208000001640 Fibromyalgia Diseases 0.000 description 1
CHDWDBPJOZVZSE-KKUMJFAQSA-N Glu-Phe-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(O)=O CHDWDBPJOZVZSE-KKUMJFAQSA-N 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
206010019663 Hepatic failure Diseases 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
208000005331 Hepatitis D Diseases 0.000 description 1
206010019773 Hepatitis G Diseases 0.000 description 1
206010019759 Hepatitis chronic persistent Diseases 0.000 description 1
101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000002227 Interferon Type I Human genes 0.000 description 1
108010014726 Interferon Type I Proteins 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
102100026017 Interleukin-1 receptor type 2 Human genes 0.000 description 1
101710149731 Interleukin-1 receptor type 2 Proteins 0.000 description 1
108010002616 Interleukin-5 Proteins 0.000 description 1
102000000743 Interleukin-5 Human genes 0.000 description 1
102000004890 Interleukin-8 Human genes 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
206010023230 Joint stiffness Diseases 0.000 description 1
206010023232 Joint swelling Diseases 0.000 description 1
241000588915 Klebsiella aerogenes Species 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
208000016604 Lyme disease Diseases 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
206010025476 Malabsorption Diseases 0.000 description 1
208000004155 Malabsorption Syndromes Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 description 1
101000960949 Mus musculus Interleukin-18 Proteins 0.000 description 1
201000002481 Myositis Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 1
108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
208000010191 Osteitis Deformans Diseases 0.000 description 1
206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
206010031264 Osteonecrosis Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
208000012868 Overgrowth Diseases 0.000 description 1
208000027868 Paget disease Diseases 0.000 description 1
235000019482 Palm oil Nutrition 0.000 description 1
206010036030 Polyarthritis Diseases 0.000 description 1
208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
241000588767 Proteus vulgaris Species 0.000 description 1
102100027378 Prothrombin Human genes 0.000 description 1
108010094028 Prothrombin Proteins 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
238000010240 RT-PCR analysis Methods 0.000 description 1
201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
208000033464 Reiter syndrome Diseases 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
208000033809 Suppuration Diseases 0.000 description 1
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
108090000340 Transaminases Proteins 0.000 description 1
102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
102000009618 Transforming Growth Factors Human genes 0.000 description 1
108010009583 Transforming Growth Factors Proteins 0.000 description 1
101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
206010054094 Tumour necrosis Diseases 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
206010046996 Varicose vein Diseases 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000007495 abnormal renal function Effects 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
208000038016 acute inflammation Diseases 0.000 description 1
230000006022 acute inflammation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
210000004404 adrenal cortex Anatomy 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003367 anti-collagen effect Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
229940125714 antidiarrheal agent Drugs 0.000 description 1
239000003793 antidiarrheal agent Substances 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
125000003435 aroyl group Chemical group 0.000 description 1
238000003556 assay Methods 0.000 description 1
229960002170 azathioprine Drugs 0.000 description 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
229940093761 bile salts Drugs 0.000 description 1
201000005271 biliary atresia Diseases 0.000 description 1
210000003445 biliary tract Anatomy 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
208000015294 blood coagulation disease Diseases 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
230000003925 brain function Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
230000000981 bystander Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
239000002975 chemoattractant Substances 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
208000019069 chronic childhood arthritis Diseases 0.000 description 1
208000037893 chronic inflammatory disorder Diseases 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
229960004126 codeine Drugs 0.000 description 1
230000000112 colonic effect Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000009849 deactivation Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000010432 diamond Substances 0.000 description 1
238000003748 differential diagnosis Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
229960004192 diphenoxylate Drugs 0.000 description 1
HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
208000007784 diverticulitis Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
201000006549 dyspepsia Diseases 0.000 description 1
239000012636 effector Substances 0.000 description 1
210000001513 elbow Anatomy 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
229940092559 enterobacter aerogenes Drugs 0.000 description 1
239000000147 enterotoxin Substances 0.000 description 1
231100000655 enterotoxin Toxicity 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
229940023064 escherichia coli Drugs 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
230000003176 fibrotic effect Effects 0.000 description 1
238000011049 filling Methods 0.000 description 1
229940047127 fiore Drugs 0.000 description 1
230000037406 food intake Effects 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
230000004927 fusion Effects 0.000 description 1
210000000232 gallbladder Anatomy 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
125000003827 glycol group Chemical group 0.000 description 1
150000002337 glycosamines Chemical class 0.000 description 1
230000012010 growth Effects 0.000 description 1
210000004247 hand Anatomy 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000036541 health Effects 0.000 description 1
208000024798 heartburn Diseases 0.000 description 1
208000031169 hemorrhagic disease Diseases 0.000 description 1
210000003547 hepatic macrophage Anatomy 0.000 description 1
208000010710 hepatitis C virus infection Diseases 0.000 description 1
201000010284 hepatitis E Diseases 0.000 description 1
230000028974 hepatocyte apoptotic process Effects 0.000 description 1
210000001624 hip Anatomy 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
210000003917 human chromosome Anatomy 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000008076 immune mechanism Effects 0.000 description 1
230000003832 immune regulation Effects 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000002055 immunohistochemical effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
108010093036 interleukin receptors Proteins 0.000 description 1
229940100601 interleukin-6 Drugs 0.000 description 1
229940096397 interleukin-8 Drugs 0.000 description 1
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
210000005206 intestinal lamina propria Anatomy 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
230000000155 isotopic effect Effects 0.000 description 1
230000008411 joint metabolism Effects 0.000 description 1
201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
210000003041 ligament Anatomy 0.000 description 1
108020001756 ligand binding domains Proteins 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
208000007903 liver failure Diseases 0.000 description 1
231100000835 liver failure Toxicity 0.000 description 1
230000003908 liver function Effects 0.000 description 1
208000018191 liver inflammation Diseases 0.000 description 1
229960001571 loperamide Drugs 0.000 description 1
RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
208000027202 mammary Paget disease Diseases 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229960001428 mercaptopurine Drugs 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229960000282 metronidazole Drugs 0.000 description 1
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
238000000302 molecular modelling Methods 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000000066 myeloid cell Anatomy 0.000 description 1
OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
210000003739 neck Anatomy 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000001703 neuroimmune Effects 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
210000002997 osteoclast Anatomy 0.000 description 1
239000002540 palm oil Substances 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000007918 pathogenicity Effects 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
230000006320 pegylation Effects 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
239000008180 pharmaceutical surfactant Substances 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
210000004180 plasmocyte Anatomy 0.000 description 1
230000004983 pleiotropic effect Effects 0.000 description 1
208000030428 polyarticular arthritis Diseases 0.000 description 1
208000005987 polymyositis Diseases 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000009465 prokaryotic expression Effects 0.000 description 1
201000008171 proliferative glomerulonephritis Diseases 0.000 description 1
229940055019 propionibacterium acne Drugs 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
229940007042 proteus vulgaris Drugs 0.000 description 1
229940039716 prothrombin Drugs 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
208000002574 reactive arthritis Diseases 0.000 description 1
239000003642 reactive oxygen metabolite Substances 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
238000012340 reverse transcriptase PCR Methods 0.000 description 1
235000021003 saturated fats Nutrition 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
230000037390 scarring Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
208000018655 severe necrosis Diseases 0.000 description 1
230000035939 shock Effects 0.000 description 1
210000002832 shoulder Anatomy 0.000 description 1
230000011664 signaling Effects 0.000 description 1
238000012868 site-directed mutagenesis technique Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000011301 standard therapy Methods 0.000 description 1
230000036262 stenosis Effects 0.000 description 1
208000037804 stenosis Diseases 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
108091007196 stromelysin Proteins 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000002344 surface layer Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000001360 synchronised effect Effects 0.000 description 1
201000004595 synovitis Diseases 0.000 description 1
210000004876 tela submucosa Anatomy 0.000 description 1
210000002435 tendon Anatomy 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
206010043778 thyroiditis Diseases 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
231100000563 toxic property Toxicity 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
102000014898 transaminase activity proteins Human genes 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
230000006433 tumor necrosis factor production Effects 0.000 description 1
230000005641 tunneling Effects 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
208000027185 varicose disease Diseases 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Addiction (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Orthopedic Medicine & Surgery (AREA)
Genetics & Genomics (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Psychiatry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Pain & Pain Management (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

NO20023962A 2000-02-21 2002-08-20 Anvendelse av en IL-18-inhibitor, en ekspresjonsvektor som omfatter den kodende sekvensen til IL-18 bindende protein og en celle som har blitt genetisk modifisert for a produsere en inhibitor av IL-18-bindende protein, i fremstillingen av et medikament for behandling og/eller forebygging av alkoholisk hepatitt. NO331971B1 (no)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP00103590		2000-02-21
EP00103597		2000-02-21
EP00121651		2000-10-04
EP00125633		2000-11-23
PCT/EP2001/001867 WO2001062285A1 (en)	2000-02-21	2001-02-20	Use of il-18 inhibitors

Publications (3)

Publication Number	Publication Date
NO20023962D0 NO20023962D0 (no)	2002-08-20
NO20023962L NO20023962L (no)	2002-08-20
NO331971B1 true NO331971B1 (no)	2012-05-14

Family

ID=27439934

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20023962A NO331971B1 (no)	2000-02-21	2002-08-20	Anvendelse av en IL-18-inhibitor, en ekspresjonsvektor som omfatter den kodende sekvensen til IL-18 bindende protein og en celle som har blitt genetisk modifisert for a produsere en inhibitor av IL-18-bindende protein, i fremstillingen av et medikament for behandling og/eller forebygging av alkoholisk hepatitt.

Country Status (31)

Country	Link
US (1)	US20030157094A1 (sk)
EP (1)	EP1257292B1 (sk)
JP (1)	JP4744763B2 (sk)
KR (3)	KR20020086540A (sk)
CN (1)	CN1322897C (sk)
AT (1)	ATE506959T1 (sk)
AU (2)	AU4063601A (sk)
BG (1)	BG66134B1 (sk)
BR (1)	BR0108514A (sk)
CA (2)	CA2683009C (sk)
CY (1)	CY1111687T1 (sk)
CZ (1)	CZ304485B6 (sk)
DE (1)	DE60144514D1 (sk)
DK (1)	DK1257292T3 (sk)
EA (1)	EA005583B1 (sk)
EE (1)	EE05423B1 (sk)
HK (1)	HK1051965A1 (sk)
HR (1)	HRP20020652A2 (sk)
HU (1)	HU227752B1 (sk)
IL (2)	IL151388A0 (sk)
ME (1)	ME00546B (sk)
MX (1)	MXPA02008079A (sk)
NO (1)	NO331971B1 (sk)
NZ (3)	NZ520122A (sk)
PL (1)	PL206549B1 (sk)
PT (1)	PT1257292E (sk)
RS (1)	RS51737B (sk)
SI (1)	SI1257292T1 (sk)
SK (1)	SK288032B6 (sk)
TR (2)	TR200502508T2 (sk)
WO (1)	WO2001062285A1 (sk)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101111103B1 (ko) *	2000-02-10	2012-02-13	아보트 러보러터리즈	사람 인터류킨-18에 결합하는 항체 및 이를 제조하고 사용하는 방법
CN1322897C (zh) *	2000-02-21	2007-06-27	应用研究系统Ars股份公司	Il－18抑制剂的应用
AU2002211744B8 (en)	2000-10-11	2008-03-20	Viron Therapeutics, Inc.	Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en)	2000-12-04	2010-05-18	Viron Therapeutics Inc.	Immunomodulatory protein and useful embodiments thereof
ES2334773T3 (es) *	2001-05-16	2010-03-16	Yeda Research And Development Co. Ltd.	Uso de inhibidores de il-18 para el tratamiento o prevencion de la sepsis.
MXPA04002565A (es) *	2001-11-30	2004-05-31	Pfizer Prod Inc	Combinacion de un inhibidor de il-1/18 con un inhibidor de tnf para el tratamiento de inflamacion.
WO2004064713A2 (en) *	2003-01-20	2004-08-05	Vib Vzw	The use of yop preoteins or rho gtpase inhibitors as caspase-1 inhibitors
JP4134166B2 (ja)	2003-04-30	2008-08-13	独立行政法人科学技術振興機構	ヒト抗ヒトインターロイキン−１８抗体およびその断片、並びにそれらの利用方法
WO2005047906A1 (en) *	2003-11-10	2005-05-26	Vertex Pharmaceuticals Incorporated	Methods for monitoring il-18
US7968684B2 (en) *	2003-11-12	2011-06-28	Abbott Laboratories	IL-18 binding proteins
JP5069000B2 (ja)	2004-06-30	2012-11-07	敦生関山	非炎症性ストレス応答の指標剤およびその利用
JP5595632B2 (ja)	2004-07-16	2014-09-24	敦生関山	Ｉｌ−１８レセプターアンタゴニスト、および当該アンタゴニストを含む薬学的組成物
DK1885753T3 (da)	2005-06-03	2011-10-03	Ares Trading Sa	Fremstilling af rekombinant II-18-proteiner
PT1891088E (pt)	2005-06-10	2011-12-19	Ares Trading Sa	Processo para a purificação da proteína de ligação il-18
EP1746167A1 (en) *	2005-07-20	2007-01-24	Apoxis SA	Method for the identification of compounds susceptible to inhibit inflammation
US8133978B2 (en)	2006-05-25	2012-03-13	Glaxo Group Limited	Humanised anti-interleukin-18 antibody
US8440195B2 (en) *	2010-11-12	2013-05-14	National University Corporation Chiba University	Inhibition of CD69 for treatment of inflammatory conditions
GB201213968D0 (en) *	2012-08-06	2012-09-19	Isis Innovation	Prevention and treatment of osteoarthritis
SG11201601717VA (en) *	2013-09-05	2016-04-28	Ab2 Bio Sa	Il-18 binding protein (il-18bp) in inflammatory diseases
RU2755691C2 (ru)	2015-03-05	2021-09-20	Аб2 Био Са	Il-18-связывающие белок (il-18bp) и антитела при воспалительных заболеваниях
CN106109497A (zh) *	2016-07-25	2016-11-16	深圳爱生再生医学科技有限公司	治疗肝硬化的干细胞制剂
CN106834449B (zh) *	2017-01-10	2019-04-30	东南大学	与原发性胆汁性胆管炎关联的白细胞介素21受体及其应用
US20210115131A1 (en) *	2018-06-14	2021-04-22	Université De Bordeaux	Treatment of Placental Chronic Histiocytic Intervillositis Using an Inhibitor of Interleukin-1
WO2023286694A1 (ja)	2021-07-13	2023-01-19	国立大学法人東海国立大学機構	炎症性腸疾患を治療するための医薬組成物
CN117647645B (zh) *	2024-01-29	2024-04-12	中国人民解放军总医院第一医学中心	Lbp、atf6、m-csfr联用在制备诊断自身免疫性肝病产品中的应用及试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5985863A (en) *	1996-09-12	1999-11-16	Vertex Pharmaceuticals, Inc.	Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5116964A (en) *	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
US5744451A (en) *	1995-09-12	1998-04-28	Warner-Lambert Company	N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
EP0936923B1 (en) *	1996-11-15	2003-12-17	Kennedy Institute Of Rheumatology	SUPPRESSION OF TNFalpha AND IL-12 IN THERAPY
US7141393B2 (en) *	1996-12-26	2006-11-28	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo	Interleukin-18-receptor proteins
JP4026923B2 (ja) *	1997-03-12	2007-12-26	株式会社林原生物化学研究所	ポリペプチド
US6087116A (en) *	1997-03-12	2000-07-11	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo	Interleukin-18 (IL-18) receptor polypeptides and their uses
IL121860A0 (en) *	1997-08-14	1998-02-22	Yeda Res & Dev	Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) *	1998-06-24	1999-12-24	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo	An artificial peptide capable of neutralizing the biological activity of interleukin-18
KR100537558B1 (ko) *	1998-09-01	2005-12-19	가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조	인터류킨-18 결합 단백질
AR022952A1 (es) *	1999-03-19	2002-09-04	Smithkline Beecham Corp	ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
KR101111103B1 (ko) *	2000-02-10	2012-02-13	아보트 러보러터리즈	사람 인터류킨-18에 결합하는 항체 및 이를 제조하고 사용하는 방법
CN1322897C (zh) *	2000-02-21	2007-06-27	应用研究系统Ars股份公司	Il－18抑制剂的应用
AU2002224417A1 (en) *	2000-10-18	2002-04-29	Immunex Corporation	Methods for treating il-18 mediated disorders

2001
- 2001-02-20 CN CNB018052932A patent/CN1322897C/zh not_active Expired - Lifetime
- 2001-02-20 CA CA2683009A patent/CA2683009C/en not_active Expired - Lifetime
- 2001-02-20 PT PT01911662T patent/PT1257292E/pt unknown
- 2001-02-20 EP EP01911662A patent/EP1257292B1/en not_active Expired - Lifetime
- 2001-02-20 KR KR1020027010645A patent/KR20020086540A/ko not_active Application Discontinuation
- 2001-02-20 BR BR0108514-0A patent/BR0108514A/pt not_active Application Discontinuation
- 2001-02-20 MX MXPA02008079A patent/MXPA02008079A/es active IP Right Grant
- 2001-02-20 TR TR2005/02508T patent/TR200502508T2/xx unknown
- 2001-02-20 JP JP2001561349A patent/JP4744763B2/ja not_active Expired - Lifetime
- 2001-02-20 AU AU4063601A patent/AU4063601A/xx active Pending
- 2001-02-20 SI SI200130994T patent/SI1257292T1/sl unknown
- 2001-02-20 EA EA200200890A patent/EA005583B1/ru not_active IP Right Cessation
- 2001-02-20 CZ CZ2002-2843A patent/CZ304485B6/cs not_active IP Right Cessation
- 2001-02-20 HU HU0300061A patent/HU227752B1/hu unknown
- 2001-02-20 IL IL15138801A patent/IL151388A0/xx unknown
- 2001-02-20 KR KR1020077010853A patent/KR20070057282A/ko not_active Application Discontinuation
- 2001-02-20 CA CA2399298A patent/CA2399298C/en not_active Expired - Lifetime
- 2001-02-20 NZ NZ520122A patent/NZ520122A/en not_active IP Right Cessation
- 2001-02-20 PL PL357554A patent/PL206549B1/pl unknown
- 2001-02-20 TR TR2002/02030T patent/TR200202030T2/xx unknown
- 2001-02-20 NZ NZ546294A patent/NZ546294A/en not_active IP Right Cessation
- 2001-02-20 US US10/204,387 patent/US20030157094A1/en not_active Abandoned
- 2001-02-20 DK DK01911662.3T patent/DK1257292T3/da active
- 2001-02-20 AU AU2001240636A patent/AU2001240636B8/en not_active Expired
- 2001-02-20 DE DE60144514T patent/DE60144514D1/de not_active Expired - Lifetime
- 2001-02-20 WO PCT/EP2001/001867 patent/WO2001062285A1/en active IP Right Grant
- 2001-02-20 EE EEP200200463A patent/EE05423B1/xx unknown
- 2001-02-20 NZ NZ535299A patent/NZ535299A/en not_active IP Right Cessation
- 2001-02-20 SK SK1208-2002A patent/SK288032B6/sk not_active IP Right Cessation
- 2001-02-20 RS YU60402A patent/RS51737B/sr unknown
- 2001-02-20 ME MEP-2008-639A patent/ME00546B/me unknown
- 2001-02-20 AT AT01911662T patent/ATE506959T1/de active
- 2001-02-20 KR KR1020077018043A patent/KR20070087256A/ko not_active Application Discontinuation
2002
- 2002-08-01 HR HRP20020652 patent/HRP20020652A2/hr not_active Application Discontinuation
- 2002-08-20 NO NO20023962A patent/NO331971B1/no not_active IP Right Cessation
- 2002-08-20 BG BG107018A patent/BG66134B1/bg unknown
- 2002-08-21 IL IL151388A patent/IL151388A/en active IP Right Grant
2003
- 2003-06-12 HK HK03104196A patent/HK1051965A1/xx unknown
2011
- 2011-07-13 CY CY20111100682T patent/CY1111687T1/el unknown

Also Published As

Publication number	Publication date
CN1322897C (zh)	2007-06-27
TR200202030T2 (tr)	2003-01-21
SK288032B6 (sk)	2012-12-03
CA2399298A1 (en)	2001-08-30
HRP20020652A2 (en)	2004-12-31
ME00546B (me)	2011-10-10
KR20070057282A (ko)	2007-06-04
NO20023962D0 (no)	2002-08-20
EP1257292A1 (en)	2002-11-20
CZ20022843A3 (cs)	2003-02-12
AU2001240636B8 (en)	2005-11-03
HUP0300061A3 (en)	2005-09-28
BG107018A (bg)	2003-09-30
DE60144514D1 (de)	2011-06-09
KR20070087256A (ko)	2007-08-27
CA2683009A1 (en)	2001-08-30
CY1111687T1 (el)	2015-10-07
KR20020086540A (ko)	2002-11-18
NZ535299A (en)	2006-06-30
AU2001240636B2 (en)	2005-10-13
ATE506959T1 (de)	2011-05-15
HU227752B1 (en)	2012-02-28
MXPA02008079A (es)	2003-02-27
NO20023962L (no)	2002-08-20
IL151388A0 (en)	2003-04-10
EE05423B1 (et)	2011-06-15
TR200502508T2 (tr)	2007-04-24
PL206549B1 (pl)	2010-08-31
EA200200890A1 (ru)	2003-02-27
JP2003523403A (ja)	2003-08-05
AU4063601A (en)	2001-09-03
PT1257292E (pt)	2011-07-05
BG66134B1 (bg)	2011-06-30
WO2001062285A1 (en)	2001-08-30
SK12082002A3 (sk)	2003-05-02
JP4744763B2 (ja)	2011-08-10
US20030157094A1 (en)	2003-08-21
HUP0300061A2 (hu)	2003-04-28
CN1404400A (zh)	2003-03-19
YU60402A (sh)	2005-09-19
PL357554A1 (en)	2004-07-26
HK1051965A1 (en)	2003-08-29
NZ520122A (en)	2005-04-29
EA005583B1 (ru)	2005-04-28
NZ546294A (en)	2008-02-29
EE200200463A (et)	2003-12-15
SI1257292T1 (sl)	2011-08-31
CZ304485B6 (cs)	2014-05-28
DK1257292T3 (da)	2011-07-18
CA2683009C (en)	2014-09-23
CA2399298C (en)	2014-04-15
EP1257292B1 (en)	2011-04-27
IL151388A (en)	2009-09-01
BR0108514A (pt)	2002-12-17
RS51737B (sr)	2011-10-31

Publication	Publication Date	Title
NO331971B1 (no)	2012-05-14	Anvendelse av en IL-18-inhibitor, en ekspresjonsvektor som omfatter den kodende sekvensen til IL-18 bindende protein og en celle som har blitt genetisk modifisert for a produsere en inhibitor av IL-18-bindende protein, i fremstillingen av et medikament for behandling og/eller forebygging av alkoholisk hepatitt.
AU2001240636A1 (en)	2001-11-15	Use of IL-18 inhibitors
US7696154B2 (en)	2010-04-13	Methods for treating interleukin-18 mediated disorders with interleukin-18 binding proteins
US20100254941A1 (en)	2010-10-07	Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
US20090074710A1 (en)	2009-03-19	Method of treatment using a cytokine able to bind il-18bp to inhibit the activity of a second cytokine
ES2365600T3 (es)	2011-10-07	Uso de inhibidores de il-18.

Legal Events

Date	Code	Title	Description
2008-01-14	CREP	Change of representative	Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS
2021-03-08	MK1K	Patent expired